0002023658

Company

Bicara Therapeutics Inc.

Pharmaceutical Preparations · BCAX

ipo trading priced Nasdaq Global Market 424B5

Filing Timeline

SEC EDGAR

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows FWP and confirms the priced prospectus.

Price $16.00 · 7,175,000 shares · Gross proceeds $149,999,780

Common Stock · Exchange Nasdaq Global Market · Ticker BCAX · Over-allotment 1,406,250 · Pre-Funded Warrants to Purchase up to 2,200,000 Shares of Common Stock · Use of proceeds Working capital, research and development, and other general corporate purposes · Underwriters Morgan Stanley, TD Cowen, BofA Securities

2026-02-26 · 0001193125-26-072875

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows 424B5 and supplements the active offering with updated prospectus details.

150,000,000 shares

common stock and pre-funded warrants · Exchange Nasdaq Global Market · Ticker BCAX · Over-allotment 22,500,000 · Pre-funded warrants exercisable for one share of common stock at $0.0001 per share · Use of proceeds To fund regulatory filings, commercial launch, development, manufacturing, and other general corporate purposes · Flags warrants

2026-02-25 · 0001193125-26-068187

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows EFFECT and confirms the priced prospectus.

2026-02-24 · 0001193125-26-067160

424B5 priced

Final prospectus supplement

Prospectus supplement filed near launch with final deal terms.

Follows 424B4 and confirms the priced prospectus.

2025-11-26 · 0001193125-25-300510

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows 424B5 and marks the registration effective.

2025-11-26 · 9999999995-25-003395

424B4 priced

Final prospectus

Final prospectus filed after pricing with final deal terms.

Follows EFFECT and confirms the priced prospectus.

Price $18.00 · 17,500,000 shares · Gross proceeds $315,000,000

Common Stock · Exchange Nasdaq Global Market · Ticker BCAX · Over-allotment 2,625,000 · Underwriters Morgan Stanley, TD Cowen, Cantor

2024-09-13 · 0001193125-24-218862

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

Follows S-1/A in the pre-IPO sequence.

2024-09-12 · 0001354457-24-000676

EFFECT effective

SEC effectiveness notice

SEC declared the registration statement effective, allowing the offering to proceed.

Follows CERT and marks the registration effective.

2024-09-12 · 9999999995-24-002816

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Bicara Therapeutics Inc. is conducting an initial public offering (IPO) of 14,705,882 shares of common stock, with an expected price range of $16.00 to $18.00 per share. The company, a clinical-stage biopharmaceutical firm, focuses on developing bifunctional therapies for solid tumors, with its lead candidate, ficerafusp alfa, targeting EGFR and TGF-β pathways. The IPO follows regulatory filings and includes underwriters Morgan Stanley, TD Cowen, Cantor, and Stifel. The company emphasizes its status as an emerging growth company and smaller reporting company, with reduced reporting requirements.

2024-09-11 · 0001193125-24-217265

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows S-1/A and registers the class of securities for exchange listing.

Bicara Therapeutics Inc. filed Form 8-A12B to register its common stock under Section 12(b) of the Securities Exchange Act of 1934, referencing its prior S-1/A registration statement. The filing incorporates by reference the prospectus from the S-1/A, which detailed the company's initial public offering (IPO) of 11,765,000 shares at an estimated price range of $16.00-$18.00 per share. The company expects its stock to be listed on The Nasdaq Global Market under the symbol 'BCAX'. The current filing confirms the registration but does not include new material details beyond the S-1/A.

2024-09-10 · 0001193125-24-216612

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1/A filing.

Range $16.00 to $18.00 · 11,765,000 shares

Common Stock · Exchange Nasdaq · Ticker BCAX · Over-allotment 1,764,750 · Use of proceeds debt repayment, working capital, acquisitions · Underwriters Morgan Stanley, TD Cowen, Cantor

Bicara Therapeutics Inc. is conducting its initial public offering (IPO) of 11,765,000 shares of common stock, with an expected price range of $16.00 to $18.00 per share. The company, a clinical-stage biopharmaceutical firm, focuses on developing bifunctional therapies for solid tumors, with its lead candidate, ficerafusp alfa, targeting EGFR and TGF-β pathways. The offering aims to fund clinical trials and business operations, with shares expected to be listed on Nasdaq under the symbol BCAX. The company is an emerging growth company with significant risks related to clinical trial outcomes, regulatory approval, and market competition.

2024-09-06 · 0001193125-24-214674

S-1/A amended

Amended registration statement

Updated registration statement filed after SEC comments or deal changes.

Updates the prior S-1 filing.

Common Stock · Exchange Nasdaq · Ticker BCAX · Underwriters Morgan Stanley, TD Cowen, Cantor

Bicara Therapeutics Inc. is conducting an initial public offering (IPO) for its common stock, aiming to raise capital to advance its clinical-stage biopharmaceutical programs. The company's lead candidate, ficerafusp alfa, is a bifunctional antibody targeting EGFR and TGF-β for solid tumors, with promising Phase 1/1b trial results in head and neck squamous cell carcinoma (HNSCC). The IPO includes underwriters Morgan Stanley, TD Cowen, Cantor, and Stifel, with an expected listing on Nasdaq under 'BCAX'. The company emphasizes its focus on transforming cancer therapies while highlighting risks related to clinical development, regulatory approval, and market competition.

2024-09-03 · 0001193125-24-211537

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is a dual-targeting antibody combining EGFR and TGF-β inhibition, currently in Phase 1/1b trials for head and neck squamous cell carcinoma (HNSCC) and other solid tumors. The company is conducting an IPO to raise capital, with underwriters including Morgan Stanley, TD Cowen, Cantor, and Stifel. Bicara emphasizes its emerging growth company status and highlights potential clinical benefits in HPV-negative HNSCC, where preliminary data show higher response rates compared to existing therapies.

2024-08-22 · 0001193125-24-205393

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Bicara Therapeutics Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its clinical-stage biopharmaceutical pipeline. The company focuses on developing bifunctional therapies for solid tumors, with its lead candidate, ficerafusp alfa, targeting EGFR and TGF-β pathways. The IPO follows positive Phase 1/1b trial results in head and neck squamous cell carcinoma (HNSCC), with plans to initiate a pivotal Phase 2/3 trial. The offering is expected to list on Nasdaq under the symbol BCAX, and the company is an emerging growth company with reduced reporting requirements.

2024-07-22 · 0000950123-24-006696

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, BCA101, is a dual-targeting antibody combining EGFR and TGF-β inhibition, showing promising Phase 1/1b trial results in head and neck squamous cell carcinoma (HNSCC). The company is preparing for an IPO, offering common stock with an expected price range and Nasdaq listing. Bicara is an emerging growth company with reduced reporting requirements and faces risks related to clinical development, regulatory approval, and dependence on BCA101.

2024-06-10 · 0000950123-24-006172